RECENT Healthcare RESEARCH
Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals’ (ALXN) Soliris.
Rite Aid (RAD) reported results for 2Q17 on Thursday, September 28, 2017. The company reported a loss of one cent per share on total sales of $7.7 billion.
On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.
Abbott Laboratories (ABT) was trading at its 52-week high of $54.75 on September 29, 2017.
Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.
On September 25, 2017, Geisinger entered into an agreement with Boehringer Ingelheim on behalf of Eli Lilly to develop a risk-prediction model for three serious health consequences associated with type 2 diabetes.
According to Medtronic (MDT), ~85% of the patients in the US who use pacemakers opt for a dual-chambered device. In fiscal 1Q18, Medtronic reported robust demand for its single-chamber pacemaker, Micra.
Let’s take a look at Wall Street analysts’ recommendations and 12-month target prices for Thermo Fisher Scientific (TMO).
On September 25, Boston Scientific (BSX) announced the launch of the Resonate family of ICD and CRT-D systems. The devices are approved by the FDA for conditional use in the MRI environment.
Headquartered in New York City, Bristol-Myers Squibb (BMY) is a US pharmaceutical company that includes products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.
On September 15, 2017, Johnson & Johnson announced a collaboration with the Department of Health and Human Services to develop a portfolio of drugs and vaccines for influenza and other infectious disease threats.
In fiscal 1Q18, Medtronic (MDT) reported revenues close to $7.4 billion, which is a 3% year-over-year (or YoY) increase.
With its recent spin-off of Varex Imaging (VREX), Varian Medical Systems (VAR) has established itself as a focused cancer management medical technology company.
On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards.
According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”
In the first half of 2017, Roche’s (RHHBY) Tecentriq reported revenues of CHF 237.0 million. In that period, the US market for Tecentriq generated revenues of CHF 229.0 million.
On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.
On September 1, 2017, the FDA approved Pfizer’s drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.
In the first half of 2017, Novo Nordisk (NVO) reported revenues of $8.3 billion compared to $8.2 billion in the first half of 2016. In 2Q17, it generated revenues of $4.2 billion.